Valeant Announces First-Quarter 2018 Results And Raises Revenue And Adjusted EBITDA (non-GAAP) Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Wall St futures pause after AI rally, focus on Mideast tensions
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Valeant Pharmaceuticals (VRX): 'A Turnaround For The Ages' - Cantor Fitzgerald
May 8, 2018 2:15 PM EDTCantor Fitzgerald analyst Louise Chen reiterated an Overweight rating and $25 price target on Valeant Pharmaceuticals (NYSE: VRX) following Q1 beat and raise.
"We think a greater appreciation for Valeant's solid execution and future growth prospects should drive upwards earnings revisions as well as multiple expansion in 2019+,"... More
